Guard Therapeutics har mottatt betinget godkjenning for fortsatt notering

Biotekselskapet Guard Therapeutics har mottatt betinget godkjenning fra Nasdaq Stockholm for fortsatt notering av sine aksjer på Nasdaq First North.

Guard Therapeutics, et svensk biotekselskap, har mottatt betinget godkjenning fra Nasdaq Stockholm. Godkjenningen gjelder fortsatt notering av selskapets aksjer på Nasdaq First North. Beslutningen ble kunngjort 16. juli 2026. Den tillater selskapet å forbli på markedsplassen under gitte forutsetninger.

Relaterte artikler

Illustration of stock exchanges affected by postponed KNDS IPO amid defense stock volatility, with flags and concerned executives.
Bilde generert av AI

KNDS postpones IPO amid volatility in defense stocks

Rapportert av AI Bilde generert av AI

The German-French defense company KNDS has postponed its planned stock market listing in Paris and Frankfurt. The firm wants to wait for better market conditions. The German government is sticking to its planned entry nonetheless.

Medical technology company SpectraCure in Lund is carrying out a rights issue that will add 34.2 million kronor if fully subscribed. The issue will finance clinical studies and regulatory applications. The share fell more than 20 percent on Monday.

Rapportert av AI

Enhanced Group Inc. started trading on the NYSE in early May following its combination with Paradise Acquisition Corp. The telehealth firm focuses on peptides and performance-enhancing products.

Biotech company Carbiotix in Lund has been declared bankrupt. The firm was delisted from Spotlight Stock Market at the end of last year.

Rapportert av AI

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

Danish drugmaker Novo Nordisk is taking a local compounding pharmacy to court in Pretoria to stop the sale of unregistered semaglutide products. The High Court application targets iDexis over patient safety concerns.

Rapportert av AI

The Egyptian government has confirmed plans to list four Armed Forces-affiliated companies on the Egyptian Exchange during a Wednesday meeting chaired by Prime Minister Mostafa Madbouly.

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis